First Human Trial of COVID-19 Vaccine Found Safe and Induces Rapid Immune ResponseMay 27, 2020
New research published in The Lancet reports that the first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans. The open-label trial in 108 healthy adults showed promising results after 28 days, while the final results will be evaluated in six months. Further trials are needed to tell whether the immune response that the vaccine elicits effectively protects against SARS-CoV-2 infection.
Between March 16 and March 27, 2020, 195 individuals were screened for their eligibility for the trials of an Ad5 vectored COVID-19 vaccine candidate in a rehabilitation center in Wuhan, Hubei province, China. Of these individuals, 108 participants (51% male, 49% female; mean age 36.3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. Participants reported mild or moderate adverse reactions such as fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]). However, the research group pointed out that the severe adverse reactions were transient and self-limiting. Antibodies and neutralizing antibodies increased significantly at day 14, and peaked 28 days post-vaccination.
"These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation," says Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study.
For more details, read the online-first article in The Lancet.
You might also like:
- Medicago Announces Positive Results of Trials for its COVID-19 Vaccine Candidate
- ISAAA Monitors Progress of Research on COVID-19
- COVID-19 Treatment Efforts Using Plant Technologies
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
See more articles:
News from Around the World
- Study Puts End to Intense Scientific Debate on Peanut's Origin
- Survey Shows Most Australians Don't Know the Difference Between Bacterial and Viral Infections
- FSANZ Rules GM Potatoes Are Safe, Calls the Public to Comment
- Researchers Find Genes to Save Ash Trees from Deadly Beetles
- Genetic Discovery Explains Barley's Sodium Tolerance
- Bumblebees Poke Leaves to Help Flowers Bloom Faster
- Protein Found to Switch on Part of Plant's Drought Defense
- Experts Identify Genome Editing and Other Innovations to Accelerate Food System Transition
- First Human Trial of COVID-19 Vaccine Found Safe and Induces Rapid Immune Response
- Coronavirus Has Two Versions and One is Not More Harmful, Study Finds
Read the latest:
- Biotech Updates (September 20, 2023)
- Gene Editing Supplement (September 13, 2023)
- Gene Drive Supplement (February 22, 2023)
Subscribe to BU: